Formulation of wheat germ oil based on nanoemulsions to mitigate cisplatin's nephrotoxic effects.

The present study was designed to fabricate wheat germ oil nanoemulsions (WGO-NEs) by using two different emulsifiers in their physical properties and their chemical structures which were Triton X-100 and Lecithin to form Triton X-100 coated WGO nanoemulsion (WGOT-NE) and Lecithin coated WGO nanoemulsion (WGOL-NE) then characterized them using Transmission Electron Microscopy, Scanning Electron Microscopy (SEM) and Dynamic light scattering (DLS) and study their biological effects against cisplatin-induced nephrotoxicity. The experimental study was performed on fifty male albino rats divided into 5 groups. healthy group, group injected with a single dose of cisplatin (CP), group injected with a single dose of CP then received WGO orally, group injected with a single dose of CP then received WGOL-NE and group injected a single dose of CP then received WGOT-NE. The results showed that the shape of the particles of WGOL-NE is spherical with poorly aggregation and average particle size is 161.2 nm while WGOT-NE is nearly spherical but with noticeable agglomeration and an average particle size of 194.6 nm. In the experimental study, the results showed involvement of cisplatin in nephrotoxicity through disturbance kidney function and histological examination of the cortical tissue of the kidney and increased biochemical markers related to inflammation, oxidative stress, and apoptotic pathway. Otherwise, treatment with WGO, WGOT-NE, and WGOL-NE increased a significant amelioration in all the biochemical markers. In conclusion, WGOT-NE and WGOL-NE were more efficient than the native WGO in attenuating the kidney damage induced by CP although WGOL-NE showed the nearest results to the control group.

JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.

BACKGROUND: Genetic mutations have been proven to be one of the major criteria in the diagnosis and distinction of different myeloproliferative neoplasm (MPN) subtypes. Therefore, the aim of this study was to determine the molecular profile of Egyptian patients with MPN subtypes and correlate with clinicopathological status. METHODS: A series of 200 patients with MPNs (92 polycythemia vera, 68 essential thrombocythemia, and 40 primary myelofibrosis) were included in this study. DNA from each sample was amplified using polymerase chain reaction to detect Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations. Sanger sequencing was used to determine the mutation types. RESULTS: Of the 200 samples, 44% had JAK2V617F and 10% were carrying CALR mutation with type 2 being the most frequent type in this study (55%). No MPL or JAK2 exon 12 mutations were detected. All clinical and hematological data had no differences with other populations except that our CALR-positive patients showed a decrease in the platelet count compared with JAK2V617F-positive patients. CONCLUSION: Our study on Egyptian patients shows a specific molecular profile of JAK2 mutation, and CALR mutation type 2 was higher than type 1.